In the background, inbound demand decreased because of the new corona, and drugstores had a considerable amount of stock. Daikoku, a significant drug chain that was investigated for allegedly violating the Antimonopoly Act for illegally returning merchandise to suppliers, compiled a plan to forestall recurrence, and was licensed by the Fair Trade Commission on the sixth.
According to the Fair Trade Commission, “Daikoku”, which operates drugstores primarily within the Kansai area, has had suppliers choose up unsold prescription drugs and cosmetics since March 2020 on the newest. It implies that the workers was dispatched from the contractor.
As a results of the survey, it was discovered that whereas opening shops focusing on inbound demand, many shops have been closed because of the affect of the brand new corona, and the truth that they’d a considerable amount of stock was the background. Even if it was achieved with the consent of the provider, it was decided that it was a violation of the Antimonopoly Act as a result of it was an unfair return that took benefit of a superior place.
In response to this, “Daikoku” submitted a “commitment plan” to forestall recurrence, together with refunding about 750 million yen as an obstacle suffered by about 80 suppliers, and on the sixth, Certified by the Fair Trade Commission.
Naohiko Komuro, Second Chief Examiner of the Japan Fair Trade Commission, mentioned at a press convention, “Even if it is because of the impact of the new corona, it is not permissible to place an unfair burden on suppliers. We will continue to prohibit monopoly in the future. We will carry out efficient and effective enforcement on cases that violate the law.”
“Daikoku deeply apologizes for the good inconvenience and concern that we’ve got brought on to our suppliers and different associated events. We will steadily implement our dedication plan and additional strengthen compliance. ” and so forth.